Get the Stockscreener App
127.12
0.07%
0.09
Intra Cellular Therapies Inc Stock (ITCI) Latest News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat
UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com
Calamos Advisors LLC Sells 3,952 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 5.3% in January - Defense World
Canaccord cuts Intra-Cellular stock rating, raises target to $132 - MSN
Intra-Cellular Therapies (NASDAQ:ITCI) Cut to “Hold” at Canaccord Genuity Group - Defense World
Moody Aldrich Partners LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
R Squared Ltd Takes $205,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
SG Americas Securities LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 - Marketscreener.com
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - Defense World
SG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World
Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN
Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN
Cantor Fitzgerald Estimates ITCI FY2025 Earnings - Defense World
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews - Benzinga
J&J Says Deals Likely to Shrink After $14.6B Intra-Cellular Buy - BioSpace
Intra-Cellular Therapies (NASDAQ:ITCI) Given "Sector Perform" Rating at Royal Bank of Canada - MarketBeat
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025 - Chemistry World
Barlow Wealth Partners Inc. Purchases Shares of 2,200 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Johnson & Johnson acquires Intra-Cellular Therapies - Pf Media
Research Analysts Issue Forecasts for ITCI FY2025 Earnings - MarketBeat
RBC Capital cuts Intra-Cellular stock rating, hikes target to $132 - MSN
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSEENFN), Intra-Cellular Therapies, Inc. (NasdaqITCI), H&E Equipment Services, Inc. (NasdaqHEES), Shutterstock, Inc. (NYSE - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, OMIC, ITCI, CCNE on Behalf of Shareholders - Morningstar
0.46%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):